[Drug-induced thrombocytopenia].
Hangaishi
Akira
A
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo.
Kurokawa
Mineo
M
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D002220:Carbamazepine / Q000009:adverse effects; D017612:Gold Compounds / Q000009:adverse effects; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011342:Procainamide / Q000009:adverse effects; D011802:Quinidine / Q000009:adverse effects; D011803:Quinine / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D013997:Time Factors
D000911:Antibodies, Monoclonal; D017612:Gold Compounds; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D002220:Carbamazepine; D006493:Heparin; D011803:Quinine; D011802:Quinidine; D011342:Procainamide; D012293:Rifampin; D000077284:Abciximab